Methodology matters: What type of research is suitable for evaluating community treatment supporters for HIV and tuberculosis treatment?

Tropical Medicine and International Health

Volumn 17, Issue 3, 2012, Pages 264-271

  Maher, Dermot ^a,b,c   Harries, Anthony D ^b,d   Nachega, Jean B ^e,f   Jaffar, Shabbar ^b  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c TUBERCULOSIS AND MALARIA   (Switzerland)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Community treatment; Human immunodeficiency virus; Methodology; Operational research; Randomised trial; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

COMMUNITY CARE; COMMUNITY HEALTH WORKER; DISEASE TREATMENT; EPIDEMIC; HEALTH POLICY; HEALTH SERVICES; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; POLICY MAKING; RESEARCH WORK; TRADE-OFF; TUBERCULOSIS;

AFRICA; ARTICLE; FUNDING; GROUP THERAPY; HEALTH CARE DELIVERY; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; METHODOLOGY; PATIENT COMPLIANCE; POLICY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUBERCULOSIS;

COMMUNITY HEALTH SERVICES; DELIVERY OF HEALTH CARE; EPIDEMICS; HIV INFECTIONS; HUMANS; OPERATIONS RESEARCH; PATIENT COMPLIANCE; POLICY; PROGRAM EVALUATION; RESEARCH DESIGN; RESIDENCE CHARACTERISTICS; TUBERCULOSIS;

AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84857365052     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2011.02920.x     Document Type: Article

References (45)

1. Adatu F, Odeke R, Mugenyi M et al. (2003) Implementation of the DOTS strategy for tuberculosis control in rural Kiboga District, Uganda, offering patients the option of treatment supervision in the community, 1998-1999. International Journal of Tuberculosis and Lung Disease 7, S63-S71.
2. Attia S, Egger M, Müller M, Zwahlen M & Low N (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23, 1397-1404.
3. Colvin M, Gumede L, Grimwade K, Maher D & Wilkinson D (2003) Contribution of traditional healers to a rural tuberculosis control programme in Hlabisa, South Africa. International Journal of Tuberculosis and Lung Disease 7, S86-S91.
4. Corbett EL, Watt CJ, Walker N et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163, 1009-1021.
5. Donnell D, Baeten JM, Kiarie J et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375, 2092-2098.
6. Dudley L, Azevedo V, Grant R, Schoeman J, Dikweni L & Maher D (2003) Evaluation of community contribution to tuberculosis care in Cape Town, South Africa. International Journal of Tuberculosis and Lung Disease 7, S48-S55.
7. Farmer P, Léandre F, Mukherjee JS et al. (2001) Community-based approaches to HIV treatment in resource-poor settings. Lancet 358, 404-409.
8. Floyd K, Skeva T, Nyirenda T, Gausi F & Salaniponi F (2003) Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. International Journal of Tuberculosis and Lung Disease 7, S29-S37.
9. Fox W (1958) The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 39, 269-274.
10. Garnett GP & Baggaley RF (2008) Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 373, 9-11.
11. Harries AD, Hargreaves NJ, Banda HT et al. (2001) Tuberculosis research in Malawi: making it count. Recent Advances and Research Updates 2, 103-118.
12. Harries AD, Rusen ID, Reid T et al. (2011) The Union and Médecins Sans Frontières approach to operational research. International Journal of Tuberculosis and Lung Disease 15, 144-154.
13. Haynes B (1999) Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving BMJ 319, 652-653.
14. Haynes RB (2001) Interventions for helping patients to follow prescriptions for medications. Cochrane Database of Systematic Reviews Issue 1.
15. Hopewell PC, Pai M, Maher D, Uplekar M & Raviglione MC (2006) International standards for tuberculosis care. Lancet Infectious Diseases 6, 710-725.
16. Jaffar S, Amuron B, Foster S et al. (2009) Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 374, 2080-2089.
17. Joint United Nations Programme on HIV/AIDS (2010) 2010 Report on the global AIDS epidemic. Geneva; 2010 (accessed 8 February 2011).
18. Kangangi J, Kibuga D, Muli J et al. (2003) Decentralization of tuberculosis treatment from the main hospitals to the peripheral health units and the community in Machakos district, Kenya. International Journal of Tuberculosis and Lung Disease 7, S5-S13.
19. Korenromp EL & Viisainen KM (2009) ART in rural Uganda - efficient scale-up with home-based care? Lancet 374, 2034-2035.
20. Maher D (2003) The role of the community in the control of tuberculosis. Tuberculosis 83, 177-182.
21. Maher D (2010) Re-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system. BMC Public Health 10, 394.
22. Maher D & Raviglione M (2009) The history of the DOTS strategy: achievements and perspectives. In: Tuberculosis (eds S Schaaf & A Zumla ) Elsevier, London, pp. 930-939.
23. Maher D, Hausler H, Raviglione M et al. (1997) Tuberculosis care in community care organisations in sub-Saharan Africa: practice and potential. International Journal of Tuberculosis and Lung Disease 1, 276-283.
24. Maher D, Floyd K, Sharma B et al. (2003) Community Contribution to TB Care: Practice and Policy. Review of Experience of Community Contribution to TB Care and Recommendations to National TB Programmes. WHO, Geneva.
25. Miti S, Mfungwe V, Reijer P & Maher D (2003) Integration of tuberculosis treatment in a community-based home care programme for persons with HIV/AIDS in Ndola, Zambia. International Journal of Tuberculosis and Lung Disease 7, S92-S98.
26. Moalosi G, Floyd J, Phatshwane J, Moeti T, Binkin N & Kenyon T (2003) Cost-effectiveness of home-based care versus hospital care for chronically ill tuberculosis patients. Francistown, Botswana. International Journal of Tuberculosis and Lung Disease 7, S80-S85.
27. Nachega JB, Chaisson RE, Goliath R et al. (2010) Randomised controlled trial of trained patient-nominated treatment supporters providing partial directly observed therapy. AIDS 24, 1273-1280.
28. Nganda B, Wang'ombe J & Floyd K (2003) Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. International Journal of Tuberculosis and Lung Disease 7, S14-S20.
29. Nyirenda T, Harries A, Gausi F et al. (2003) Decentralisation of tuberculosis services in an urban setting, Lilongwe, Malawi. International Journal of Tuberculosis and Lung Disease 7, S21-S28.
30. Okello D, Floyd K, Adatu F, Odeke R & Gargioni G (2003) Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. International Journal of Tuberculosis and Lung Disease 7, S72-S79.
31. Omaswa F (2003) The "Community TB Care in Africa" project. (Editorial). International Journal of Tuberculosis and Lung Disease 7, S1.
32. Orrell C (2005) Antiretroviral adherence in a resource-poor setting. Current HIV/AIDS Reports 2, 171-176.
33. Padian NS, Buvé A, Balkus J, Serwadda D & Cates W (2008) Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 372, 585-599.
34. Sibbald S & Roland M (1998) Understanding controlled trials: why are randomised controlled trials important? British Medical Journal 316, 201.
35. Sinanovic E, Floyd K, Dudley L, Azevedo V, Grant R & Maher D (2003) Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. International Journal of Tuberculosis and Lung Disease 7, S56-S62.
36. Smith JH & Whiteside A (2010) The history of AIDS exceptionalism. Journal of the International AIDS Society 13, 47.
37. Victora CG, Black RE, Boerma JT & Bryce J (2011) Measuring impact in the Millennium Development Goal era and beyond: a new approach to large-scale effectiveness evaluations. Lancet 377, 85-95.
38. von Elm E, Altman DG, Egger M et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453-1457.
39. World Health Organization (1974) World Health Organization Expert Committee on tuberculosis, 9th report. World Health Organization Technical Report Series No. 552. WHO, Geneva, Switzerland.
40. World Health Organization (2003a). Adherence to Long-Term Therapies. Evidence for Action. World Health Organization, Geneva, Switzerland.
41. World Health Organization (2003b). Treatment of Tuberculosis. Guidelines for National Programmes, 3rd edn. (WHO/CDS/TB/2003.313). WHO, Geneva, Switzerland.
42. World Health Organization (2010a) Global tuberculosis control: epidemiology, strategy, financing. WHO Report 2010. Geneva. (accessed 8 February 2011)
43. World Health Organization (2010b). Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 revision) (accessed 9 February 2011).
44. World Health Organization, UNAIDS and UNICEF (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva. (accessed 9 February 2011).
45. Zachariah R, Harries AD, Ishikawa N et al. (2009) Operational research in low-income countries: what, why, and how? Lancet Infectious Diseases 9, 711-717.